Advertisement
Screener

KURA ONCOLOGY, INC. (KURA) Accumulated Other Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

KURA ONCOLOGY, INC. Accumulated Other Comprehensive Income

KURA ONCOLOGY, INC. (KURA) had Accumulated Other Comprehensive Income of $1.02 million as of 2025-12-31, per its 10-K filed 2026-03-05.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-03-05

  • 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.02M.
  • 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $711.00K.
  • 2025-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $974.00K.
  • 2024-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $764.00K.
Period endAccumulated Other Comprehensive Income (Loss), Net of Tax
2025-12-31$1.02M
10-K · filed 2026-03-05
2025-06-30$711.00K
10-Q · filed 2025-08-07
2025-03-31$974.00K
10-Q · filed 2025-05-01
2024-12-31$764.00K
10-K · filed 2026-03-05
2024-09-30$1.12M
10-Q · filed 2024-11-07
2024-06-30-$463.00K
10-Q · filed 2024-08-08
2024-03-31-$816.00K
10-Q · filed 2024-05-02
2023-12-31-$1.27M
10-K · filed 2025-02-28
2023-09-30-$3.54M
10-Q · filed 2023-11-02
2023-06-30-$5.22M
10-Q · filed 2023-08-09
2023-03-31-$5.90M
10-Q · filed 2023-05-10
2022-12-31-$8.03M
10-K · filed 2024-02-27
2022-09-30-$9.42M
10-Q · filed 2022-11-03
2022-06-30-$7.82M
10-Q · filed 2022-08-03
2022-03-31-$6.65M
10-Q · filed 2022-05-04
2021-12-31-$1.79M
10-K · filed 2023-02-23
2021-09-30-$194.00K
10-Q · filed 2021-11-04
2021-06-30-$393.00K
10-Q · filed 2021-08-05
2021-03-31-$82.00K
10-Q · filed 2021-05-06
2020-12-31$46.00K
10-K · filed 2022-02-24
2020-09-30$224.00K
10-Q · filed 2020-11-05
2020-06-30$557.00K
10-Q · filed 2020-08-06
2020-03-31$561.00K
10-Q · filed 2020-05-04
2019-12-31$331.00K
10-K · filed 2021-02-24
2019-09-30$332.00K
10-Q · filed 2019-11-05
2019-06-30$161.00K
10-Q · filed 2019-08-01
2019-03-31$18.00K
10-Q · filed 2019-05-07
2018-12-31-$131.00K
10-K · filed 2020-02-25
2018-09-30-$123.00K
10-Q · filed 2018-11-05
2018-06-30-$93.00K
10-Q · filed 2018-08-06
2018-03-31-$68.00K
10-Q · filed 2018-05-08
2017-12-31-$49.00K
10-K · filed 2019-03-05
2017-09-30-$14.00K
10-Q · filed 2017-11-07
2017-06-30-$22.00K
10-Q · filed 2017-08-07
2017-03-31-$19.00K
10-Q · filed 2017-05-15
2016-12-31-$18.00K
10-K · filed 2018-03-12
2016-09-30$11.00K
10-Q · filed 2016-11-07
2016-06-30$45.00K
10-Q · filed 2016-08-10
2016-03-31$11.00K
10-Q · filed 2016-05-11
2015-12-31-$87.00K
10-K · filed 2017-03-14
2015-09-30$1.00K
10-Q · filed 2015-11-13
2015-06-30-$14.00K
10-Q · filed 2015-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Apnimed, Inc. (APMD)United States$0.899B
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Savara Inc (SVRA)United States$1.044B-9.10
Theravance Biopharma, Inc. (TBPH)$0.885B16.40